Lichenoid drug eruption associated with imatinib mesylate therapy.

Dimitrios Alexandris, Nektarios Alevizopoulos, Leonidas Marinos, Georgios Kanellis, Charikleia Gakiopoulou

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Jan

filter terms:

Imatinib Mesylate (IM), a tyrosine kinase inhibitor, has been reported to cause several adverse reactions, most of them with cutaneous involvement. Non- Lichenoid IM associated skin reactions have been sufficiently- recorded. To our knowledge, Lichenoid Drug Eruption (LDE) is recorded in a minority of registries. To describe an LDE induced case by IM treatment. Histological Confirmation and promptly dermatological consultation relieved successfully the cutaneous adverse event. Ongoing expansion of IM usage in a wide spectrum of new indications is more likely to make physicians experience such LDE cutaneous side effects more often. Hence, they should be highly suspicious to early detect these distinct histologic entities, handle these undesired complications and guarantee satisfactory immediate outcomes, avoiding frivolous IM dosage modifications.

Citation

Dimitrios Alexandris, Nektarios Alevizopoulos, Leonidas Marinos, Georgios Kanellis, Charikleia Gakiopoulou. Lichenoid drug eruption associated with imatinib mesylate therapy. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2023 Jan;29(1):252-257